stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
65.85
1.81
+2.83%
Follow CELC
Alert me
Celcuity, Inc. (CELC) EPS (diluted)
Celcuity, Inc.'s EPS (diluted) for fiscal 2025 was −$3.79, compared with −$2.83 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.30. Over the past ten years it has ranged from −$3.79 (fiscal 2025) to −$0.39 (fiscal 2015) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 6 consecutive fiscal years. Celcuity, Inc. ranks 422nd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.79 | — |
| FY2024 | −$2.83 | — |
| FY2023 | −$2.69 | — |
| FY2022 | −$2.64 | — |
| FY2021 | −$2.21 | — |
| FY2020 | −$0.92 | — |
| FY2019 | −$0.72 | — |
| FY2018 | −$0.74 | — |
| FY2017 | −$0.84 | — |
| FY2016 | −$0.52 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.44 | — |
| Mar 2026 | −$0.97 | — |
| Dec 2025 | −$0.97 | — |
| Sep 2025 | −$0.92 | — |
| 36 more quarters | Free account |
Against its own ten years
Low −$3.79
High −$0.39
Ten-year median
−$0.92
Current reading's percentile
9
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. | −$4.30 |
| IDYA IDEAYA Biosciences, Inc. compare | −$4.49 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item